BBIO vs CL · rev $221.9M vs P/E 34, rev $20.38B
BridgeBio Pharma Inc (BBIO) versus Colgate-Palmolive Company (CL) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Colgate-Palmolive Company (CL) is a household & personal products company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported CL revenue for 2025-12-31 was $20.38B. Net income was $2.13B. Revenue was up 1.4% from 2024-12-31 to 2025-12-31. CL currently screens at market cap $70.88B and trailing P/E 34.3.
BBIO currently screens at market cap $13.24B. CL currently screens at market cap $70.88B and trailing P/E 34.3.
Not investment advice. Open the BBIO and CL stock pages for the full models.
Not investment advice.